Day1, July 5, 13:30 p.m., Sesson B:
Collecting and processing big bata: Possibilities & Challenges

Anna Bauer Mehren is a Bioinformatician by training and leads the Data Science Department in Roche Pharma Research and Early Development in Germany. Her team supports pre-clinical and clinical research teams through data management and data analysis, applying in particular Artificial Intelligence methods. They are analyzing high-dimensional data such as imaging data, genomic information, and data from electronic health records to better understand diseases and develop personalized therapies.
 
Anna Bauer Mehren holds a PhD in Bioinformatics and Biomedical Informatics from the University of Pompeu Fabra in Barcelona and Master in Bioinformatics from the Ludwig-Maximilians-Universität and the Technische Universität München. She completed her postdoc education at the Faculty of Biomedical Informatics at Stanford University in the USA.

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Carsten Brockmeyer is the CEO of Formycon AG, Munich, one of the fastest growing Biotech-Pharma enterprises. Formycon focuses on treatments in ophthalmology, immunology and other key chronic diseases. Before joining Formycon, Carsten has held senior management positions at Baxter, Hexal, and Sandoz/Novartis. From 1998 to 2009, he was General Manager of Hexal Biotech GmbH. Carsten founded Brockmeyer Biopharma GmbH in 2010, a pharma and biotech consultancy, and helped to establish Formycon AG in 2012. Carsten holds a doctoral degree in human biology from Hannover Medical School and worked as postdoctoral fellow at the National Institutes of Health in Bethesda U.S.A., and the Institute of Immunology, LMU Munich, before entering the biopharma industry. His work in the field of biopharmaceuticals has been recognized with prestigious scientific awards.

https://www.formycon.com/en/company/management/

Day 1, July 5, 10:00 a.m.: Welcome-Session and
Day 1, July 5, 16:15 p.m.: KeyNote Lecture

Born on February 3, 1969 in Stuttgart. Study of chemistry at the Universities of Stuttgart and Heidelberg. Research student at the University of Bristol (UK) and Cambridge (UK). Diploma in chemistry in 1995 at the University of Heidelberg, doctorate at the University of Heidelberg/EMBL Grenoble (France) in 1998. Predoctoral fellow in Grenoble (France) from 1995 to 1998, postdoctoral fellow at Stanford University (USA) from 1999 to 2001. Tenure-track professor of biochemistry at the University of Munich from 2001 to 2003. Professor of biochemistry at the University of Munich from 2004 to 2014. Director of the Gene Center of the University of Munich (LMU) from 2004 to 2013. Director at the Max Planck Institute of Biophysical Chemistry since 2014.

https://www.mpinat.mpg.de/635625/cv_cramer

Day2, July 6, 4:30 p.m., #7 Livetalk:
Präzisionsmedizin: Die Chancen der frühen Diagnose

Professor Eva Susanne Dietrich is a pharmacist with more than 20 years professional experience in reimbursement, health politics, and drug evaluation.

She graduated at the University of Heidelberg, obtained her PhD in the field of pharmacoeconomic methodology from the University of Tuebingen and received a Master’s degree on Health Technology Assessment and Management from the University of Barcelona.

Professor Dietrich served as a deputy member of the Federal Joint Committee (G-BA) which specifies for almost 90 percent of the German population the services in medical care that are reimbursed. In parallel, she led the Department of Drugs, Remedies and Aids at the German National Association of Statutory Health Insurance Physicians (KBV) which concludes contracts with health insurance funds and other parties of the health care sector on the part of the 140,000 office-based physicians and psychotherapists in Germany. In the following years, she organized a scientific institute for Techniker Krankenkasse, one of the largest health insurance funds in Germany, and was responsible for the Management Division Health Sciences. Thereafter, she managed a scientific consulting firm in Basel for eight years and founded the Institute of Evidence-based Positioning in the Healthcare Sector in 2018.

An important emphasis of her professional and academic activities is the critical review of the evidence of new drugs, their classification in the existing care context and, more specifically, early benefit assessments and the German AMNOG process as well as the compilation of AMNOG dossiers.

Since 2000, Eva Susanne has been teaching at the department of clinical pharmacy at the University of Bonn, where she holds a honorary professorship and also leads a module in the drug regulatory affairs degree programme. Apart from this she taught pharmacoeconomics, evidence based medicine, and benefit legislation e.g. at the universities of Hamburg, Berlin and Marburg.

www.dietrich.healthcare

Day1, July 5: 13:30 Session C: Nanoscience-Biotech - Developments at the interface

https://www.dietzlab.org/people/bio-dietz/

Day 1 and 2, Host and Moderator

Managing Director/CEO of  Bio^M Biotech Cluster Development GmbH and of Bio^M AG, Martinsried. Spokesman of "Bavarian Biotechnology Cluster" mandated by the Bavarian Government, Spokesman of "Leading Edge Cluster Munich m4 - personalized medicine" (2010-2015).

https://www.bio-m.org/en/about-biom/team/management/domdey.html

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Institute of Pharmacology and ToxicologyTechnical University Munich
Position Full Professor (W3) and Chair

Advanced Professional Positions
since 2021 Vice-Coordinator of the Munich site within the German Center for
Cardiovascular Research (DZHK)
since 2019 Coordinator of the Collaborative Research Centre TRR/SFB 267 “Non-coding RNA in the cardiovascular system”
2013-2019 Vice Dean for Research, TUM School of Medicine
2011-2020 Coordinator of the Munich site within the German Center for Cardiovascular Research (DZHK)
2011-2013 Member of the Executive Board of the German Cardiac Society (DGK)
2010-2013 Vice-Chair and Chair (2011) of the Commission for Experimental Cardiology of the German Cardiac Society (DGK)

Professional Experience and Postdoctoral Training
since 2008 Full Professor and Chair (W3), Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
2005-2008 Professor of Clinical Pharmacology at the University of Wuerzburg (W2)
2004-2008 Group Leader, Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, University of Wuerzburg
2003-2004 Appointment as Fellow in Cardiovascular Research, Massachusetts General Hospital, Harvard Medical School, Boston
1999-2003 Postdoctoral position at the Institute for Pharmacology and Toxicology,
Bayerische Julius-Maximilians-Universität Wuerzburg

Academic Education
1997-2001 PhD thesis, MD/PhD-program of the faculties of Biology and Medicine,
University of Wuerzburg (summa)
1993-1995 MD thesis, Max-Planck-Institute of Biochemistry, Laboratory of Molecular Biology, Martinsried (summa)
1989-1996 Studies in Medicine, Universities of Regensburg, Munich (Germany) and Harvard (USA)

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Franziska Faber studied biology at the Martin-Luther University (Halle/Saale, Germany). Her doctoral work at the Robert Koch Institute (Wernigerode, Germany) introduced her to the field of enteric bacterial infections. In 2011, she started her postdoctoral work in the lab of Andreas Bäumler at the University of California, Davis (USA). Here, she studied the mechanisms by which antibiotic treatment lowers “colonization resistance” against the enteric pathogen Salmonella enterica. More specifically, she explored how inflammation-associated changes in intestinal nutrients contribute to intestinal colonization of S. enterica. In 2018, she joined the Center for Infectious Disease Research (ZINF) in Würzburg as a Young Investigator to study the previously unexplored RNA biology of the intestinal pathogen Clostridioides difficile. Since 2021, she is a Junior Professor and leads a research group at the Helmholtz Institute for RNA-based Infection Research in Würzburg.

bayresq.net – Rbiotics

Day1, July 5: 13:30 Session C: Nanoscience-Biotech - Developments at the interface

Dr. Niels Fertig is a Physicist by training and did study at the University of Goettingen, Germany, University of California in San Diego, USA and the University Munich. He is the Chief Executive Officer of Nanion Technologies GmbH, the company he founded in 2002 at the end of his PhD work.

Nanion is a leading provider of instrumentation for ion channel drug discovery and has grown over the last 20 years to a company with over 100 employees worldwide. Nanions instrumentation indeed revolutionized the way drug companies screen ion channels as it dramatically increases the throughput of patch clamp measurements while keeping the data quality high as compared to other high throughput methods. Furthermore, we have developed instrumentation for ips cell research, cardiotoxicity screening and parallel membrane transporter protein assays.

Nanion combines trusted scientific support with exceptional instrumentation to accelerate successful drug development and scientific discoveries.

https://www.nanion.de/en/company/management-board.html

Day1, July 5: 13:30 Session B:
Collecting and processing big bata: Possibilities & Challenges

PD Dr. med Benjamin Friedrich is currently the Chief Medical Officer of Temedica and its recently launched data analytics platform Permea.
He completed his postdoctoral studies at the Royal College of Surgeons in Ireland, before acting as an assistant physician in the departments of Radiology and Neuroradiology at Klinikum rechts der Isar der TU München and Universitätsklinikum Leipzig. After acting as a consultant for both Stryker and iSchemaView, Dr. Friedrich returned to Klinikum rechts der Isar der TU München as an attending physician, before joining Temedica in his current role. Dr. Friedrich also currently acts as an assistant professor at TU München.

As Chief Medical Officer at Temedica, Dr. Friedrich leads the organization’s medical-strategic development work with a focus on data analytics and patient-reported outcomes, alongside all scientific research. With over 60 publications and many years of clinical work and extensive experience as a consultant for international medical technology companies, the former senior physician brings a wealth of experience from medical research and patient care.

Having worked as a practitioner in neurosurgery and neuroradiology and as a researcher for over a decade, Dr. Friedrich decided to take the next step into the world of digital health in order to actively shape the direction of the future of healthcare. His goal is simple: to improve the healthcare system through digitization and data-driven innovation.

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

Ingo Gellrich is the Country Manager Germany of Zifo RnD Solutions, a global scientific solutions and service provider, specialized in the industries of pharmaceuticals and life sciences. Passionate about people and enthusiastic about technology, Ingo focuses on enabling his colleagues through his knowledge of Zifo’s key industries and services. His expertise assists him in tactically bringing together Zifo's experts, customers and partners, to find strategic solutions for challenges at hand. With 20+ years of experience as software developer, chemical structure DB admin, liaison manager and program & project manager in the Pharma and MES industry, he has enabled Zifo’s evolution across Germany and Europe. Ingo also holds a degree in Business Informatics and is a PMP with a good standing since 2009.

Day1, July 5: 13:30 Session B:
Collecting and processing big bata: Possibilities & Challenges

Dr. Roland Geyer is currently the Chief Operating Officer of lifespin, a deep data company that maps human health based on metabolic information.
After studying chemistry and earning his doctorate in medicinal chemistry at the University of Regensburg, he joined numares AG as project leader and built and headed the research services department for NMR based multiparameter quantification and metabolomics.

2018 he and his team changed over to lifespin GmbH, a 2017 founded start-up. After setting up operations and service labs he took over as COO and assumed operational responsibility for the implementation of lifespin’s strategy.
Based on its metabolic profiling platform, combining NMR based liquid biopsy, a proprietary profiling software and a database with >150k profiles, lifespin captures digital snapshots of individual metabolism and enables the classification of individual samples. lifespin standardized a baseline for human health to detect distinct deviations in the human metabolome caused by diseases. lifespin’s solutions are accessible via lifespin service labs or as cloud-based SaaS and thus, will learn from many and benefit everyone.

Day2, July 6: Morning-Panel

Elke Glasmacher is since November 2021 heading the Chapter of Biomarker Discovery in Roche Diagnostics solutions, responsible for the implementation of a new strategy, new governance structures as well as acquisition of collaborations in the Open and Innovation space. From 2017-2021 she had successfully led and buildup a department for Immune and Cell Biology in Roche Pharma (pRED) in a transformation and initiated various changes, implementing the way for more innovation, modern ways of working and diverse and inclusive environment.

In her education, she worked at Grünenthal in Aachen, studied in Cologne Biology and moved for her main courses in Biochemistry to Boston and then the Max Planck of Biochemistry. She then switched to immunology for her PhD thesis and described a mechanism that prevents autoreactive T cells in lupus. She moved in 2010 to Genentech as a Postdoctoral Fellow and discovered a genomic
regulatory element that drives differentiation programs of immune cells. In 2013 she established an independent investigator laboratory at the Helmholtz Center Munich where she continued to work on molecular factors driving immune cell fate and activation.

Day2, July 6, Morning Panel

Thomas Gudermann was born in Lippstadt, Germany, in 1960. From 1981 to 1988 he studied Medicine at the University of Münster, Germany. After a postdoctoral period at Baylor College of Medicine, Houston, TX, USA, from 1989 to 1992, he returned to Münster University Hospital as a clinical resident. In 1998 he received his habilitation in Pharmacology and Toxicology from Freie Universität Berlin.

In 1999 Gudermann was appointed Chair of Pharmacology at the University of Marburg and served as Vice Dean of the Medical Faculty from 2002 to 2007. Since 2008 he is Professor and Chair of Pharmacology and Toxicology at LMU Munich and served as Vice Dean of LMU Faculty of Medicine from 2018 to 2021. Gudermann is an elected member of the National Academy of Sciences Leopoldina since 2009. 

Gudermann has been serving as spokesperson of two research consortia funded by the German Research Foundation (DFG): since 2014 Collaborative Research Center TRR 152 “TRiPs to Homeostasis”, and Research Training Group 2338 “Targets in Toxicology” since 2018. In addition, he is speaker of the Elite Master Program “Human Biology” funded by the State of Bavaria since 2018. In 2020, Gudermann co-founded the biotech start-up Cirlo GmbH.

In 2020, Gudermann was elected speaker of the whole DFG Review Board (Fachkollegium) Medicine.

As of October 2021, Thomas Gudermann is Dean of the Medical Faculty of LMU Munich.

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Peter Hammann joined Hoechst AG in 1986 in the area of infectious diseases. In 1995 he moved to Bombay, as head of research Hoechst, India. After returning to Germany 1997 he was the head of the core research department of Hoechst Marion Roussel in Frankfurt. 2000 he moved to New Jersey, USA as head of lead generation for Aventis (merger of HMR and Roussel Uclaf.) Being back in Frankfurt in 2005 after Sanofi merged with Aventis, he was one of the key leaders to rebuild infectious disease (ID) research within of the new company. As head of external opportunities for ID at Sanofi, he completed several major key research cooperation agreements and licensing in this field.

Since 2014 he was leading the Sanofi-Fraunhofer natural product center, a public private partnership (PPP), with a major focus on novel antibiotics. After the transfer of ID from Sanofi to Evotec in July 2018, he joined Evotec as SVP Infectious Diseases. In June 2020 he started his part time retirement program and works as a consultant for antibiotic and natural product research.

He is member of several international committees and acts as scientific advisor, for example in the council of the Robert-Koch-Foundation, the research initiative Infect Control 2020, the Research Campus middle Hessen, the biotech startup Smatbax as well the HIPS center in Saarbrücken.

Peter Hammann received his diploma in biochemistry from the technical University of Darmstadt in 1982 and his doctoral degree in Organic Chemistry from the University of Hannover in 1985 with highest honors. He completed his habilitation in medicinal chemistry in 1992 at the Veterinary University of Hannover, where he was lecturing for more than 20 years as an adjunct Professor. From 2016 to 2022 he was is Honorary Professor at the Justus-Liebig-University of Giessen and since 2020 he is Honorary Professor at the Saarland University.

He filed more than 30 patent applications, published almost 60 peer-reviewed articles, and presented around 100 lectures as invited speaker.

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

After being a founding part of company in the 2000 dot-com Bubble, Andreas, studied Computational Linguistics at the Center for Information and Language processing at the LMU. Driven to science, he joined the Gene Center Munich in 2009 to push the in-house Scientific Computing, building compute clusters and pipelines for Cryo-EM and genome sequencing. After some years back in computational linguistics consulting for some high profile companies, he rejoined the Gene Center in 2016 as part of LAFUGA Genomics to explore Nanopore Sequencing in the early days. Since 2019 he is part of the office of Dr. Ulrike Kaltenhauser, leading the digital networking core project of bayresq.net.

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

Bettina Hermann started her career in the IP field in 2001 in a German IP boutique. Bettina studied biology at the Technical University Munich with an emphasis on microbiology, genetics, biochemistry and clinical chemistry. She received her PhD in biology from the Technical University Munich and did practical work at the Max-Planck-Institute of Psychiatry, Munich, before she became Postdoc at the IGBMC in Illkirch Strasbourg, France.

Bettina has experience in advising small and mid-size biotech companies, in particular in the field of cancer therapies, and providing patentability, validity and FTO analyses for investors. She also represents clients in opposition proceedings before the German Patent and Trademark Office and the European Patent Office and in nullity proceedings before the Federal Patent Court as well as in infringement proceedings before German regional courts.

Bettina is head of the Munich office of V.O.

Day1, July 5: 13:30 Session B:
Collecting and processing big bata: Possibilities & Challenges

Ralf Huss, MD, Ph.D., is adjunct Professor of Pathology and Managing Director of the Institute of General Pathology and Molecular Diagnostics, University Hospital in Augsburg (Germany), where he also chairs the Institute for Digital Medicine. Dr. Huss is board certified in anatomical, experimental, and molecular pathology with more than 30 years of training and experience in histopathology, immunology, translational cancer research, and oncology in Zurich (Switzerland), Seattle (USA) and Munich (Germany). Previously, Dr. Huss held different senior positions in the pharmaceutical industry (Roche, AstraZeneca). He also serves as Honorary Professor at the University College Dublin (Ireland) and as Lecturer of Nanotechnology and Biomaterials at the Faculty of Chemistry, Technical
University of Munich (Germany). His research interest is mainly on the use of machine and artificial intelligence in routine tissue diagnostics and biomarker discovery, and he has (co-)authored more than 150 peer-reviewed articles, reviews, book chapters and books in related areas.

Day1, July 5, 13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine

Christian Itin joined Autolus as Chairman of the Board of Directors at the inception of the company and subsequently also took on the role of Chief Executive Officer. In April 2021, a new Chairman was appointed with Christian remaining as Chief Executive Officer.
Previously he was Chief Executive Officer and Chairman of the Board of Directors of Cytos Biotechnology Ltd, a public biotechnology company that merged with Kuros Biosurgery Holding Ltd, and until May 2019 he served as Chairman of the Board of Directors of the merged entity, renamed Kuros Biosciences Ltd.
Prior to joining Cytos, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company which was acquired in March 2012 by Amgen, Inc. for USD 1.2 billion in cash. Micromet pioneered T-cell engaging antibodies and with blinatumomab developed the first approved product in this field.
After serving in senior management roles at Micromet, Christian was appointed Chief Executive Officer in 2004. Prior to joining Micromet in 1999, Christian co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA.
Christian received a diploma in biology and a PhD in cell biology from the University of Basel, Switzerland. In addition, Christian also performed post-doctoral research at the Biocenter of Basel University and at Stanford University School of Medicine, CA, USA.

Day2, July 6, Host and Moderation

Monika Jones is one of the leading bilingual journalists and presenters in Germany. As an English speaking news anchor at Germany's global TV broadcaster, Deutsche Welle, she is familiar to a wide international audience, especially in North America, Asia, Africa and the Middle East.

Monika is also one of Germany's leading bilingual presenters of international conferences and business events. Her regular clients include top multinational companies, government ministries, European institutions and NGOs. Monika's specialist areas are economics, corporate relations, human resources, and transport & logistics.

Monika presented one of the largest Livestream events ever as the official presenter of the European Space Agency's historic Rosetta mission, which successfully landed the Philae space probe on a comet!

Day1, July 5, 13:30, Host Session A
Innovative technologies: How molecular advances could shape the medicine of the future

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Dr. Hitto Kaufmann is a biopharma leader with over 20 years of experience in research, development and manufacturing with a track record in development of about 100 biological therapeutic entities. Prior to joining Pieris, Dr. Kaufmann spent five years at Sanofi, where he held several executive positions in Industrial Affairs and R&D. During his time there, he led efforts to build a strong cross-divisional end-to-end technology platform for Sanofi Biologics that included several strategic deals. He also went on to head Global Biopharmaceutics Development, managing over 700 employees across three sites tasked with drug substance and drug product technical development, analytics, clinical supply and release. Finally, he oversaw key strategic projects on digitalization and data sciences, as well as the integration of the Ablynx platform into the Sanofi network. Before his tenure at Sanofi, Dr. Kaufmann spent more than a decade at Boehringer Ingelheim, most recently in the Biopharmaceuticals division as Vice President, Process Science. He began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne.

Dr. Kaufmann received his Ph.D. in Natural Science, focusing on cell culture technology, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in biotechnology from the Technical University of Braunschweig and the Scripps Research Institute. He currently serves as Vice Chairman of the European Society of Animal Cell Technology and has authored over 25 peer-reviewed publications.

Day2, July 6: Morning-Panel

Magdalena Kempa is the commercial Managing Director of smartbax, a company pioneering the fight against AMR with novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. As Managing Director with focus on business, Magdalena is responsible for overall project management, finance, business development, legal and investor relations.

As Partner at Blue Ribbon Partners GmbH, Magdalena has further deep understanding of biotech venture co-founding and building. She has international working experience, 10+ years of experience as advisor for life science venture building and incubation and is an active advisor for venture teams in various programs: i.e. Federal Government of Germany #wirvsvirus Covid-19 Hackathon and AHEAD Life Science venture track sponsored by Sartorius AG.

Magdalena holds an M.A. in Communication Science from the University of Vienna and is Fellow of the Venture Finance Programme from the University of Oxford.

Day2, July 6, 4:30 p.m., #7 Livetalk:
Präzisionsmedizin: Die Chancen der frühen Diagnose

Education:

1988-1995 Medical School, University of Göttingen
1995 Final medical exam and M.D. certificate

Research and professional experience:

1995-1998 Research Fellow, Internal Medicine/Hematology and Oncology, University of Göttingen
1998-2005 Research Fellow, Dept. of Internal Medicine III, University of Munich 1999 M.D. thesis/Dr. med., Universtity of Göttingen
2001-2005 Head immunophenotyping, Laboratory for Leukemia Diagnostics, University of Munich
2003 Specialization Internal Medicine
2003 Specialization Hematology and Medical Oncology
2004 Postdoctoral lecture qualification, University of Munich

Since August 2005 MLL Munich Leukemia Laboratory (co-owner), Managing Director, Head of Immunophenotyping
Since 2007 Reviewer for hematology for DAkkS (German accreditation body) 2011 International Cytometry Certification Examination (ICCE)
2013 Appointment as Professor
2013 Member of the DAkkS Sectorial Committee on medical laboratories
2021 ICCS Senior Councilor for Quality

Munich, May 11th 2022

Day2, July 6, 4:30 p.m., #7 Livetalk:
Präzisionsmedizin: Die Chancen der frühen Diagnose

After finishing Medical School in Erlangen and Munich, Germany, Dr. Klein´s professional stations included postdoctoral fellowships at the Department of Physiology at the University of Munich and at the National Heart, Lung and Blood Institute (NHLBI) in Bethesda. His received his clinical training at the Medical Policlinic of the University of Munich and at the Department of Clinical Chemistry at the University Hospital Grosshadern.

After successfully passing the board examinations for Clinical Pathology and Human Genetics, Dr. Klein left the university and started his career as an entrepreneur. He founded MEDIGENOMIX GmbH, a genomic services company, which today is part of the Eurofins group. Shortly after, Dr. Klein founded the Center for Human Genetics and Laboratory Diagnostics in Martinsried and IMGM Laboratories GmbH, being the Medical Director and CEO of both companies to date. In a joint transaction in 2018, both companies have become part of the international Medicover group (Sweden). In 2019, Dr. Klein founded acmaios GmbH, an investment company for seed financing start-ups in biotech and digital health.

Dr. Klein is author of more than 120 scientific publications and book contributions and serves as a field editor for the Journal of Laboratory Medicine. He is also a member of several medical associations and teaches Clinical Chemistry at the University of Munich. Dr. Klein served as a board member of the M4 cluster “Personalized Medicine” steering committee in Martinsried, an initiative supported by the State Government of Bavaria to improve treatment of cancer and other diseases. From 2017 until 2022 he served as elected Board Member of the Association of German Human Geneticists (BVDH). Recently, Dr. Klein was a founding member and appointed Vice-President of the newly formed network initiative “Personalized Medicine".

Day1, July 5,

11:00 p.m., Moderator of the discussion panel

13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine

Ulrike Köhl is a full Professor for Immune Oncology at the University of Leipzig, Germany and the director of the Fraunhofer Institute for Cell Therapy and Immunology since 2017 and holds the position of a full Professor and director of the Institute of Cellular Therapeutics at Hannover Medical School since 2012, respectively. She holds a degree in biology supplemented by a medicine study. She worked at the MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. She is an international leading expert in the development and manufacturing of cell and gene therapies in cancer and regenerative medicine and collaborates with both international industry and academic partners. She has a specific own research focus on primary human NK cells as well as chimeric antigen receptor (CAR) expressing T and NK effector cells. The Köhl team has been responsible for one of the first NK cell trial in Europe. Currently, Prof. Köhl is heading “SaxoCell”, a cluster for cell and gene therapy, funded by the Germany federal government as a future and excellence initiative. In addition, she is leading two EU consortia (“Mature-NK” and the IMI “ImSAVAR”). Prof. Köhl is a member of numerous national and international societies and a committee member of scientific advisory boards of different companies.

Day 1, July 5: Welcome-Session

KeyNote

Short biography:
Heyo K. Kroemer was born in 1960 in Leer, Germany. From 1978 to 1983 he studied Pharmacy at the Technical University of Braunschweig. In 1992 he received his habilitation in Pharmacology and Toxicology from the Eberhard Karls University of Tübingen. In the same year he was awarded the Paul-Martini-Preis.

In 1998 Kroemer was appointed Chair of General Pharmacology at the University of Greifswald and from 2000 to 2012 he served as Dean of the Medical Faculty of the University of Greifswald.

From 2012 to 2019 Kroemer was Chairman of the Managing Board of the University Medical Center Göttingen and Dean of the Faculty of Medicine.

In 2018 he was elected member of the National Academy of Sciences Leopoldina. Furthermore he is member of the National Academy of Science and Engineering (acatech) and of the Berlin-Brandenburg Academy of Sciences and Humanities.

Since 2007 Kroemer had been a board member of the German Medical Faculty Association, serving as its president from 2012 to 2019. He is board member of the Association of German University Hospitals (VUD), furthermore member of the AAHC (Association of Academic Health Centers) President’s Council on Health Security.

As of September 2019 Kroemer is Chief Executive Officer of the Charité – Universitätsmedizin Berlin.

https://www.charite.de/service/person/person/address_detail/kroemer/

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Dr. Stefan Löffler studied Biochemistry and Pharmaceutical Sciences and Technologies in Munich and Tübingen. Having finished his PhD in the wider field of biomedicine and pharmacology at the university of Bonn, he joined Explicat Pharma in 2021.
He fills the role of CMC-Projectmanager focusing on pharmaceutical development and process analytical technology.

Day1, July 5: 13:30 Session C: Nanoscience/Medtech/Biotech - developments at the interface

Dr. Henriette Maaß was born in 1987 in Hanau, Germany. From 2007 till 2013 she studied Physics at the University of Würzburg where she received her PhD in 2017. Her main research focus was the investigation of semiconducting and metallic thin films by photoelectron spectroscopy.

From 2017 till 2019 she worked at Singulus Technologies AG on implementing and optimizing thin-film deposition processes for semiconductor devices.

In 2019 she started the spin-off project NanoStruct resulting in the foundation of NanoStruct GmbH in February 2021 where Henriette Maaß is founder & CEO.

She has won several prices including the “Wilhelm-Conrad-Röntgen-Wissenschaftspreis” in 2017 and the Northern Bavarian Businessplan Contest in 2021.

Her current focus with NanoStruct lies on the development of plasmonic sensors that can be applied in optical spectroscopy.

Day2, July 6, 12:30 p.m., Session B:
Impact of environment and way of living

Lara Maier is a doctor who, after working at the University Hospitals rechts der Isar in Munich and the Charité in Berlin, now fully devotes herself to digital medicine. As Senior Consultant at goetzpartners, a consulting agency, she is currently responsible for building up their healthcare-consulting chapter with strong focus on strategy and digitalization in the health care economy. She uses her expert knowledge as a medical consultant for start-ups and companies to build the necessary bridge between "medical reality" and "digital transformation".

Before, she was Medical Director at  Caspar Health , a not-anymore-startup for digital rehabilitation, which is fully recognized by the German Pension Fund by now. As a certified member of the British Society of Lifestyle Medicine (BSLM) and nutritional physician (DGEM), she is particularly interested in prevention and Ayurvedic medicine. In addition,  she's a board member, KeyNote Speaker and enjoys moderating as well as writing (scientific) articles about her favorite topics.

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

William Menzer is currently a third year PhD student with Eisbach Bio, where he handles all of the chemistry work – from computational docking and AI based binding predictions, through classical medicinal chemistry, all the way to coordination of GMP upscales and CMC duties. William started his journey toward his current role at Eisbach by completing his bachelor’s and master’s degrees in molecular biochemistry and biophysics at Illinois Tech in 2019 in Chicago, only a short distance from where he grew up. He moved to Munich after being accepted into the IMPRS-LS program as a PhD student with Andreas Ladurner in 2019 and started at Eisbach shortly thereafter.

https://www.eisbach.bio/

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Dr. Michael P. Menden is a Junior Group Leader at the Institute of Computational Biology (Helmholtz Zentrum München) since 2019, is heading the Menden Lab, and is Head of the DZD Computational Biology Unit. He was awarded an ERC Starting Grant in 2020, and the McGuigan Rising Star Award in Drug Discovery by Cardiff University in 2022. Previously, Dr. Menden worked as Senior Scientist in Oncology Bioinformatics, AstraZeneca, UK. He was a PhD student and postdoctoral fellow at EMBL-EBI, UK. His PhD was awarded in Computational Biology by the University of Cambridge, UK in 2016.

Day2, July 6, 12:30 p.m., Session B:
Impact of environment and way of living

Ferdinand von Meyenn has been Assitiant Professor of the Institute of Food Nutrition and Health at the ETH Zurich since January 2019.

Ferdinand studied Biochemistry at the TU Müchnen, Germany, before moving to ETH Zürich for his PhD to study metabolism and type-2 diabetes. After his graduation, he joined Prof Wolf Reik at the Babraham Institute in Cambridge, UK, and investigated epigenetic mechanisms during development and ageing. In 2017 he joined King’s College London as a Research Fellow and then moved in 2019 to ETH Zurich where he was appointed Assistant Professor for Nutrition and Metabolic Epigenetics. His research focuses on the complex relationship between nutrition, metabolism and the epigenome, with the aim to contribute to the development of novel strategies to combat obesity and metabolic disease.

https://epigenetics.ethz.ch/

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Hannelore Meyer studied Biology at the Technical University Munich. Focussing on protein analytics, she did her PhD in the group of Prof. Lottspeich at the Max Planck Institute of Biochemistry, Martinsried. She continued her analysis of the hypusine containing protein at the Sandoz Reseach Institute in Vienna.

After working with Prof. Reinhard Fässler (Max Plnck Institute of Biochemistry) on b1 integrin, she then joined the Institute for Medical Microbiology, Immunology and Hygiene (TUM). Her group works on the development diagnostic tests and of novel antibacterial small molecules. The project on a novel carbapenemase inhitor with stand alone antibiotic activity received support via BMBF grants, Go.Bio initial funding, andm4 Award.

Day1, July 5, 13:30 p.m., Sesson B:
Collecting and processing big bata: Possibilities & Challenges

Dr. Georg Muenzenrieder has held various positions in the Bavarian ministerial administration since completing his training as a fully qualified lawyer and obtaining his doctorate in 2009. After returning from a secondment to the Federal Foreign Office to the Permanent Representation of the Federal Republic of Germany to the EU in Brussels from 2015 to 2017, he has been Head of Division for Fundamental Issues of Digitalization in Health and Care, Future and Innovation Projects in the Bavarian State Ministry of Health and Care since 2017.

Since 2019 he has also been chairman of the federal and state working group on digitalization in the healthcare sector and chairman of the gematik advisory board. Since 2020, in addition to his work as a Head of Division, he has also been the deputy head of the Unit for Cooperation with Relevant Institutions as part of the Corona Pandemic Task Force of the Bavarian State Ministry of Health and Care.

Day2, July 6, 12:30 p.m., Session B:
Impact of environment and way of living

Barbara Munz studied Biotechnology, Biochemistry and Chemistry at the Universities of Stuttgart, Tübingen and LMU München and graduated with a Master’s Degree in Biochemistry in 1994. She did her Ph.D. at LMU Munich and in Sabine Werner’s lab at the Max Planck Institute of Biochemistry in Martinsried, where she worked on the molecular mechanisms of wound repair. Starting in 1999, she did a three-year postdoc at Helen Blau’s lab in Stanford, focusing on skeletal muscle regeneration. After a further postdoc in Walter Birchmeier’s group at MDC Berlin, she started her own lab at the Charité. Since then, she has been focusing on the molecular mechanisms that control skeletal muscle plasticity, specifically in response to physical exercise and training. As of today, she is head of the “Skeletal Muscle Plasticity Lab” at the Department of Sports Medicine of University Medicine Tübingen. Within the last few years, transducing the results of basic research into practical implications in the context of a healthy lifestyle has been one of her major goals.

Foto: Beate Armbruster, Copyright Universitätsklinikum Tübingen

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

Day1, July 5: 13:30 Session C: Nanoscience-Biotech - Developments at the interface

https://www.dynamic-biosensors.com/dynamic-biosensors/

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Carsten Rudolph, CEO and president, pharmacist by training, received his PhD from the Department of Pharmacy of the FU Berlin. Since 2003 he is group leader at the Dr. von Haunerschen Kinderspital of the Ludwig Maximilians University, Munich. He is lead inventor of the SNIM® RNA-Technology and co-inventor of numerous drug delivery patent applications. Carsten Rudolph received his post-doctoral lecture qualification at the Department of Pharmacy, FU Berlin in 2009. In 2005 Carsten Rudolph received the prestigious BioFuture Award of the BMBF which is the highest endowed young investigator award in Germany.

https://ethris.com/management/

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

David Rudolph studied chemistry at the Karlsruhe Institute of Technology (KIT) and completed his PhD at the end of 2021. As part of the research group of Prof. Feldmann, he worked  in close cooperation with different collaborators from the medical field on the development of novel drug delivery systems for the transport and release of various pharmaceutical drugs. As a postdoctoral researcher he is now working on the further optimization of these systems as well as on the evaluation of potential commercialization.

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

CV Amit Salvi

Day1, July 5,

11:00 p.m., Moderator of the discussion panel

13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine

Day2, July 6, 12:30 p.m., Session B:
Impact of environment and way of living

Mathias V. Schmidt received his undergraduate and graduate training at the University of Bayreuth, Germany and the University of Delaware, USA, where he first became involved in stress research through the guidance of Prof. Seymour “Gig” Levine. He continued his research in the field of stress and development during his PhD training at the University of Leiden, the Netherlands, with Prof. Ron de Kloet. Mathias then moved to Munich, Germany, where he started his postdoctoral work at the Max Planck Institute of Psychiatry. Since 2010 he is leading the research group “Neurobiology of Stress Resilience” at the Max Planck Institute of Psychiatry and is a lecturer at the Ludwig-Maximilians-University. In his research, he is striving to gain a deeper, mechanistic understanding of the biological processes driving stress vulnerability and resilience, which ultimately allow the implementation of targeted pharmacological and non-pharmacological interventions to strengthen stress resilience and reduce disease burden.

Day1, July 5, 13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine

Cynthia Sharma is a full professor and Chair of Molecular Infection Biology II at the Institute of Molecular Infection Biology (IMIB) at the Julius-Maximilians University of Würzburg.

She studied Biology at the Heinrich-Heine-University of Düsseldorf and obtained her PhD in bacterial RNA biology at the Max Planck Institute for Infection Biology, Berlin (MPIIB). After short postdoctoral work at the MPIIB and the National Institutes of Health in Bethesda (USA), she joined the Research Center for Infectious Diseases (ZINF) in Würzburg as an independent junior group leader in 2010. Since 2017 she is heading the newly established Department of Molecular Infection Biology II at the IMIB in Würzburg. Moreover, she is spokesperson of the ZINF in Würzburg since 2018.

Research in her lab focuses on mechanisms of gene regulation in stress response and virulence control of bacterial pathogens as well as biology and mechanisms of prokaryotic RNA-based CRISPR-Cas immune systems.

Her research was recognized with several awards, such as the 2011 Postdoc award in Microbiology of the Robert Koch Foundation and the German Association for Hygiene and Microbiology (DGHM), the 2013 DGHM Young investigator award, and  the Heinz-Maier-Leibnitz-Preis of the Deutsche Forschungsgemeinschaft (DFG) in 2015. Recently, she was awarded an 2021 ERC Consolidator Grant.

More information/lab website:
http://www.imib-wuerzburg.de/research/sharma/group-leader/

Day 1, July 5, 17:15 p.m.: Afternoon Session

Before becoming CEO of Ascenion in 2001, Christian Stein headed the project management department at the Fraunhofer Patent Centre for German Research. Since November 2020 he is Chairman of the Board of TransferAllianz, the German Knowledge and Technology Transfer Association, representing the TTOs of around 100 scientific institutions. Christian is also a chairman of the MGC Foundation and a member of the International Strategy Committee of the American Association of University Technology Managers (AUTM). From 2014 to 2016 he was President of ASTP, the European Association of Knowledge and Technology Transfer Professionals and Board Member of the global Association of Technology Transfer Professionals (ATTP) from 2012 until 2015.

Christian Stein has founded several companies in and outside the biotechnology field. He is a consultant and advisor to various EU programs as well as regional and national expert groups, serves as a member of the Supervisory Board of ISAR Bioscience in Munich and is on the advisory board of a number of biotechnology companies.

Christian holds a PhD in molecular biology and obtained a Master of Science (MSc) in Management of Intellectual Property Law from QMW in London.

Day1, July 5: 13:30 Session C: Nanoscience and Biotech - Development at the interface

Apl. Prof. Felix von Stetten studied agricultural sciences, biotechnology, and completed his PhD in Microbiology at the Technical University of Munich. In 2020 he started in the diagnostics industry, and in 2004 he joined in the Laboratory for MEMS Applications at IMTEK, University of Freiburg, where he was involved in lab-on-a-chip research. In 2008, Felix von Stetten became head of the Lab-on-a-Chip division at Hahn-Schickard, and in 2020 executive board member of the Hahn-Schickard Institut für Mikroanalyse Systeme. Felix von Stetten and his team have designed and developed several molecular diagnostic point of care tests which were transferred to the in-vitro diagnostics industry.

Day1, July 5: 12:45 p.m.
Networking, pitches, company presentations

Dr. Karim Tabiti was born in New York (U.S.A.). He majored in Biology and Business administration at the Technische Universität in Munich, Germany and the University of Regensburg. After graduating as Dipl. Ing. agr (univ) he moved to Vienna where he completed his PhD in molecular Biology at the Institute of Molecular Pathology (IMP).

Following his training, Karim Tabiti led a research team in the field of oncology from 1992 to 1996 as a postdoc at the Institute of Molecular and Cell Biology (IMCB) in Singapore

In 1996 Karim Tabiti joined Boehringer Mannheim, which was acquired by the Roche Group. With increasing responsibility Karim Tabiti held several senior strategic management positions within the Roche Diagnostics division, including Roche Applied Science, Integrated Cancer Care Unit and Roche Molecular Systems. His passion over 17 years has been the development and commercialization of molecular diagnostic tests and systems.

In 2013 he resumed the responsibility of the corporate product marketing and business development for Immune Diagnostic Systems (IDS) in the UK as a member of the executive team.

As a general manager, Karim Tabiti began 2015 to established Biotype Innovation GmbH in Dresden, a joint venture between QIAGEN N.V. and Biotype Diagnostics GmbH. Two years later he took on the responsibility of managing the Biotype Diagnostics GmbH (later Biotype GmbH) as chief executive officer.

Since April 2022 Karim Tabiti is supporting Biotype from the MDG Holding, where is has the function of the chief strategy officer.

In addition, Karim Tabiti has been acting in the advisory board of several biotech companies since 2013.

Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic

Michael Thormann is co-founder of Origenis and co-inventor of MOREsystem® and MolMind®. He leads the technology platform development, implementation, and its application throughout the drug discovery and development process. As CSO, he is responsible for the success of the cross-functional, highly interdisciplinary team and empowers scientific excellence and technological leadership, and industrial applicability. Prior Origenis, as Head of Molecular Modeling at Morphochem, he invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimization techniques, that together with Cippix® and BRAINstorm® have lead to Origenis’ proprietary AI Innovation Platform.

Day2, July 6, 4:30 p.m., Livetalk - Präzisionsmedizin: Die Chancen der frühen Diagnostik

https://www.br.de/nachricht/jeanne-turczynski-autorenprofil-100.html

Bild: Bernhard Schmid

Day2, July 6, 3:30 p.m., KeyNote

https://www.helmholtz-munich.de

Day2, July 6, 12:30 p.m., Session B:
Impact of environment and way of living

Dr. Moritz Völker-Albert is co-founder and managing director of EpiQMAx GmbH. Since his bachelor's degree in biomedicine in Marburg, he has been working on epigenetics, i.e. the interplay between environmental influences and the human genome. During his master's degree in Leiden, Netherlands, he got to know the technology of mass spectrometry intensively and was able to combine both topics during his doctorate at the LMU in Munich. In consequence, EpiQMAx connects both subject areas and uses them for epigenetic profiling.

Day1, July 5, 10:00 a.m., Welcome-Note

Roland Weigert was born in 1968 and grew up in Hohenried in the district
of Neuburg-Schrobenhausen in Upper Bavaria.

After passing his A levels and finishing his training as a wholesale and foreign
trade merchant, he joined the Federal Armed Forces in 1990 as an officer.
At the same time, Roland Weigert studied Business and Organizational Sciences at the University of the Federal Armed Forces in Munich and graduated with a diploma degree in Business Administration “Dipl.-Kaufmann (Univ.)”.

From 1999, he worked as economic officer in the district of Neuburg-Schroben-
hausen and was elected in 2008 Administrative Head of District of Neuburg-
Schrobenhausen. He held this position for more than 10 years and left this
position after his election to the Bavarian State Parliament in 2018.

In 2018, Roland Weigert became Vice Minister and member of the Bavarian
State Government.

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Klaus Weinberger is the founder and managing partner of Weinberger & Weinberger Life Sciences Consulting, the co-founder and CEO of Metaron Diagnostics, and the Managing Director of Health Hub Tirol.

A biochemist and virologist by training, his professional focus is on bioanalytics, in vitro diagnostics, and vaccine development. Klaus started his research on the energy metabolism of hyperthermophilic archaea but spent most of his academic career in hepatitis virology, working for the WHO reference center for viral hepatitis at the University of Regensburg, where he developed and implemented one of the first diagnostically used real-time PCR assays for viral load testing.

Later on, he (co-)founded and/or led several biotech and IT companies, e.g. Biocrates Life Sciences in Innsbruck, Austria, where he implemented the first fully integrated technology platform for targeted metabolomics, WWLSC in Regensburg, Germany, a consultancy with a focus on diagnostics and vaccine development, sAnalytiCo in Belfast, UK, a data analytics
company specialising in network inference, and, most recently, Metaron Diagnostics in Munich, Germany, developing in vitro diagnostic kits for chronic kidney disease and endometriosis.

At Health Hub Tirol, Klaus now creates a regional ecosystem for biotech and medtech start-ups by providing domain expertise, lab infrastructure and funding programs in an integrated tech transfer center.

Day2, July 6, 9:00 a.m. Plenum Keynote and Morning-Panel

Current Role: Clemens Wendtner, MD, is Professor of Medicine and Chief Physician at Munich Clinic Schwabing, an academic hospital of the Ludwig-Maximilian University (LMU) of Munich.

Clinical Focus & Interest: Prof. Wendtner has been principal investigator for numerous phase I-III clinical studies, and his scientific interests focus on development of new therapies in the field of chronic lymphocytic leukemia (CLL). Furthermore, he is a specialist in infectious diseases with special focus on COVID-19.

Experience: Prof. Wendtner completed his MD qualification at the University of Münster, Germany, in 1993. Thereafter, he received a postdoctoral training at the Max-Planck-Institute in Martinsried, Germany, and at the National Institutes of Health (NIH), Bethesda, MD, until 1995. Following a clinical fellowship at LMU, he gained his German and US license in Internal Medicine before specializing as a hematologist and oncologist at the same institution. Prof. Wendtner received his postdoctoral lecture qualification at LMU in 2002 and received his Full Professorship of Medicine at the University of Cologne in 2004. He was Deputy Director of the Department of Hematology and Oncology at the University of Cologne until 2011. Since 2011 he is Chief Physician of the Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine at the Munich Clinic Schwabing, an academic teaching hospital of the Ludwig-Maximilian University in Munich. During the COVID-19 pandemic, he has treated the first German patients with COVID-19 in his centre and acted as consultant for the National Academy of Sciences (Leopoldina) and the Federal as well as the Bavarian Ministry of Health. Prof. Wendtner is an auditor in internal medicine, hematology/oncology at the Bavarian Chamber of Physicians in Munich (since 2011) and an expert for benefit assessment of oncology drugs at the Federal Joint Committee in Berlin (since 2015).

Affiliations: As a founding member of the German CLL Study Group (GCLLSG), Prof. Wendtner participates on the Steering Committee and is the GCLLSG’s Secretary. He has published more than 200 articles in peer-reviewed journals including NEJM, Cell, Nature, Lancet, Blood, and others. Since 2019, he is Deputy Director of the Scientific Ethics committee of LMU.

Day1, July 5, 13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine

Dr. Gerald Wiegand is leading Moderna's activities in Germany. He has more than 20 years of experience in the life sciences industry and was most recently responsible for the German business unit for rare metabolic diseases at Takeda since 2017. Previously, Gerald Wiegand worked in oncology at Bristol-Myers Squibb and Eli Lilly. He established the German subsidiary of the oncology diagnostics company Genomic Health (now Exact Sciences) and the German professional association of Accredited Laboratories in Medicine (ALM e.V.). Gerald Wiegand holds a PhD in Biophysics from the Technical University of Munich and a MBA from INSEAD.

Day1, July 5, 13:30 p.m., Sesson B:
Collecting and processing big bata: Possibilities & Challenges

https://www.digimed-bayern.de/partner/leitung.html

Jens joined Bio^M in early 2018 to help setting up the Bavarian P4 medicine lighthouse project DigiMed Bayern. Since it’s start he is heading DigiMed Bayern operational part as Managing Director. The project aims to implement digitally driven predictive, preventive, personalized and participatory medicine of the future in the examplary field of atherosclerotic diseases. It is funded by the Bavarian State Ministry of Health and Care with a total of above € 24 Mio with runtime until 2024.

In addition, Jens supports Bio^M and the Bavarian Biotech Cluster with his expertise in international Business Development and Digital Health.

2006 to 2018 he was responsible for setting up and scaling DNA-related services within different companies of the Eurofins group. This comprised DNA-Forensics, ancestry and paternity testing as well as animal and plant breeding, food analysis and cell genotyping. 2001 to 2006 he worked in Sales and Product Management for the Munich area based SME Biomax Informatics AG.

Jens has a PhD in Protein Engineering from the Gene Center of the Ludwig Maximilian University of Munich and a Diploma in Biology (Population Genetics) from Christian-Albrechts-Universität zu Kiel.

Day 1, July 5: Welcome-Session

Discussion Round

Short biography:
Professor Ernst-Ludwig Winnacker is currently Professor Emeritus at the University of Munich (LMU).

He studied chemistry at ETH Zurich, Switzerland, where he obtained his PhD. He did postdoc research at the University of California in Berkeley, USA, and the Karolinska Institute. He held professorships at the University of Cologne and the Institute of Biochemistry, University of Munich. 1984-1997 he was Director of the Laboratory of Molecular Biology at the Gene Center in Munich, Germany.

Ernst-Ludwig Winnacker served as President of the German Research Foundation (DFG) from 1998 to 2006, and subsequently as first Secretary General of the European Research Council (ERC). From 2009 to 2015 he was Secretary General of the Human Frontier Science Program Organization.

He was awarded Doctores honoris causa from the Veterinary University of Vienna, and the Medical Faculties of the Universities of Würzburg and Munich.

He is a member of the German National Academy of Sciences Leopoldina and the National Academy of Medicine of the US National Academies of Sciences. He received several awards, among them the Order of the Rising Sun, Gold and Silver Star from Japan and the International Science and Technology Cooperation Award from the People’s Republic of China, the Leibniz Medal and the Robert Koch Medal.

Professor Winnacker’s main research interests are virus/cell interactions, the mechanisms of gene expression in higher cells and prion diseases.

Day 2, July 6, 12:30 p.m., Session C:
Novel biochemical approaches for next generations of antibiotics

Colonel Roman Wölfel is the director of the Bundeswehr Institute of Microbiology and military consultant microbiologist, virologist and infectious disease epidemiologist. As adjunct Professor, he teaches at the Technical University and the Bundeswehr University in Munich.

For twenty years, his research and work has focused on the diagnosis and bioforensics of dangerous pathogens and biotoxins. In this context, Prof. Wölfel supervises numerous projects to improve biosafety and biosecurity in Europe, Africa and Asia. As an expert military advisor, he supports Germanys participation in international organisations, e.g. for the further development of the Biological Weapons Convention.

Prof. Wölfel’s involvement in the field of military medicine is based on a mix of operational and academic activities that affect both the military and civilian health sectors. His interests include infectious diseases, tropical medicine, emergency medicine and modern training and teaching methods.

Day1, July 5, 10:00 a.m., Welcome-Note and
Day2, July 6, 10:00 a.m. Morning panel: Looking Ahead - How can we prepare for future threats to our healthcare systems?

https://www.stmwi.bayern.de/ministerium/organisation/